Impact of a physician-supervised exercise-nutrition program with testosterone substitution in partial androgen-deficient middle-aged obese men
- PMID: 22783306
- PMCID: PMC3390090
- DOI: 10.3724/SP.J.1263.2011.00201
Impact of a physician-supervised exercise-nutrition program with testosterone substitution in partial androgen-deficient middle-aged obese men
Abstract
Background: Partial androgen deficiency syndrome in the aging male is associated with signs of aging such as a development of abdominal obesity, sexual dysfunction, increase body fat, weight gain and the development of cardiac disease.
Objective: We assessed the outcome of a commercially available physician supervised nutrition and exercise program with concomitant testosterone replacement therapy in middle age obese men with partial androgen deficiency in order to reduce cardiac risks factors.
Methods: Fifty-six self referred men without diabetes mellitus, hypertension, or cardiovascular disease (ages 52.3 ± 7.8 years) were randomly selected from a large cohort. Baseline weight, body fat composition, fasting glucose, hemoglobin A1c and fasting lipid levels, as well as free and total testosterone levels were assessed. All patients were assessed and followed 6-18 months after initiation of the program. The program consisted of a low glycemic load balanced nutrition diet, a recommended structured daily exercise program of 30-60 minutes, as well as once to twice weekly intramuscular testosterone injections (113.0 ± 27.8 mg).
Results: At follow up, weight was reduced from 233.9 ± 30.0 pounds (lbs) to 221.3 ± 25.1 lbs (P < 0.001), BMI was reduced from 33.2 ± 3.3 kg/m(2) to 31.3 ± 2.8 kg/m(2) (P < 0.0001). Total body fat was 27.1% ± 5.2% vs. 34.3% ± 5.7% at baseline (P < 0.0001). Fasting glucose was reduced from 95.3 ± 14.4 mg/dL to 87.5 ± 12.6 mg/dL (P < 0.0001). Total cholesterol was reduced from 195.4 ± 33.0 mg/dL to 172.7 ± 35.0 mg/dL (P < 0.005). No clinically significant adverse events were recorded.
Conclusions: Testosterone replacement therapy in middle aged obese men with partial androgen deficiency appeared safe and might have promoted the effects of a weight reduction diet and daily exercise program as long as an adequate physician supervision and follow up was granted. The combination therapy significantly reduced coronary risk factors such as glucose intolerance and hyperlipidemia.
Keywords: aging; androgen deficiency; heart disease; testosterone.
Similar articles
-
Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency.Aging Male. 2003 Mar;6(1):1-7. Aging Male. 2003. PMID: 12809074 Clinical Trial.
-
Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease.Am Heart J. 2020 Jun;224:65-76. doi: 10.1016/j.ahj.2020.03.016. Epub 2020 Mar 20. Am Heart J. 2020. PMID: 32335402 Clinical Trial.
-
The obesity paradox, weight loss, and coronary disease.Am J Med. 2009 Dec;122(12):1106-14. doi: 10.1016/j.amjmed.2009.06.006. Epub 2009 Aug 13. Am J Med. 2009. PMID: 19682667
-
Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.Adv Exp Med Biol. 2017;1043:473-526. doi: 10.1007/978-3-319-70178-3_22. Adv Exp Med Biol. 2017. PMID: 29224108 Review.
-
Testosterone, body composition and aging.J Endocrinol Invest. 1999;22(5 Suppl):110-6. J Endocrinol Invest. 1999. PMID: 10442580 Review.
Cited by
-
Strength training as a supplemental therapy for androgen deficiency of the aging male (ADAM): study protocol for a three-arm clinical trial.BMJ Open. 2019 Sep 5;9(9):e025991. doi: 10.1136/bmjopen-2018-025991. BMJ Open. 2019. PMID: 31492775 Free PMC article.
-
Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study.J Endocrinol Invest. 2014 Apr;37(4):401-11. doi: 10.1007/s40618-014-0066-9. Epub 2014 Mar 18. J Endocrinol Invest. 2014. PMID: 24639122
-
Effects of Aerobic Exercise Combined with Oyster Peptide Supplement on the Formation of CTX-induced Late-Onset Hypogonadism in Male Rats.Reprod Sci. 2023 Apr;30(4):1291-1305. doi: 10.1007/s43032-022-01068-w. Epub 2022 Sep 12. Reprod Sci. 2023. PMID: 36097247
-
Testosterone supplementation and body composition: results from a meta-analysis of observational studies.J Endocrinol Invest. 2016 Sep;39(9):967-81. doi: 10.1007/s40618-016-0480-2. Epub 2016 May 30. J Endocrinol Invest. 2016. PMID: 27241317 Review.
-
Risks of testosterone replacement therapy in men.Indian J Urol. 2014 Jan;30(1):2-7. doi: 10.4103/0970-1591.124197. Indian J Urol. 2014. PMID: 24497673 Free PMC article. Review.
References
-
- Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Invest. 1999;22:110–116. - PubMed
-
- Kravchenko AIa, Provotorov VM. Age-related androgen deficiency in men with ischemic heart disease. Adv Gerontol. 2008;21:311–313. - PubMed
-
- Hofer HG. Men in a critical age: Kurt Mendel and the controversy over the male climacterium. Urologe A. 2011;50:839–845. - PubMed
-
- Nau JY. Normality of the libido (andropause) Rev Med Suisse. 2010;6:1518–1519. - PubMed
-
- Delev DP, Kostadinova II, Kostadinov ID, et al. Physiological and clinical characteristics of andropause. Folia Med. 2009;51:15–22. - PubMed
LinkOut - more resources
Full Text Sources
Medical